An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

A new study led by researchers at the University of Minnesota has found a three-way link among antibiotic use in infants, changes in the gut bacteria, and disease later in life. The imbalances in gut microbes, called dysbiosis, have been tied to infectious diseases, allergies and other autoimmune disorders, and even obesity, later in life.

Danish researchers at the University of Copenhagen have discovered how to map more than one protein at a time, when proteins repair damaged DNA. It is a discovery that will help accelerate the process of developing better and gentler cancer treatments. The discovery has just been described in an article in the renowned scientific journal, Science.

Researchers have uncovered a unique connection between diabetes and Alzheimer's disease, providing further evidence that a disease that robs people of their memories may be affected by elevated blood sugar, according to scientists at Washington University School of Medicine in St. Louis.

A University of Cincinnati (UC)-led research team has found that generic formulations of tacrolimus, a drug used post-transplant to lower the risk of organ rejection, are just as good as the name-brand version. The findings were presented Sunday, May 3, by lead investigator Rita Alloway, PharmD, UC research professor of medicine and

Scientists moved a step closer toward coaxing the body into producing its own replacement blood vessels after discovering that suppressing parts of the innate immune system may raise the chances of a tissue engineered vascular graft's success. In a report appearing in the May 2015 issue of The FASEB Journal scientists showed that

A new study found that drugs used to treat multiple sclerosis have soared in price in the past two decades, in some cases more than 700 percent, even though newer drugs have come to the market - a process that normally should have stabilized or reduced the cost of at least the older medications.